JonesTrading analyst Justin Walsh has reiterated their bullish stance on TLSI stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Justin Walsh has given his Buy rating due to a combination of factors including TriSalus Life Sciences’ strong financial performance and innovative product developments. The company’s second-quarter revenue of $11.2 million exceeded expectations, showing a significant year-over-year and quarter-over-quarter growth, primarily driven by the expanded use of their TriNav system in liver embolization procedures.
Additionally, the launch of the TriNav FLX Infusion System, which offers improved navigation and flexibility, has been well-received in the market, enhancing the user experience for healthcare professionals. The positive clinical outcomes, such as the successful use of the TriNav system in thyroid artery embolization and the promising results from ongoing studies, further support the potential for continued revenue growth and clinical benefits, reinforcing the Buy rating.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $11.00 price target.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TLSI in relation to earlier this year.